Impaired counter-regulation of interleukin-1 by the soluble IL-1 receptor type II in patients with chronic liver disease

Scandinavian Journal of Gastroenterology

Volumn 43, Issue 11, 2008, Pages 1360-1365

  Ludwiczek, Othmar ^a   Vannier, Edouard ^b   Moschen, Alexander ^c   Salazar Montes, Adriana ^d   Borggraefe, Ingo ^b   Gabay, Cem ^e   Enrich, Barbara ^c   Kaser, Arthur ^c   Siegmund, Britta ^f   Dinarello, Charles ^e   Tilg, Herbert ^a,c  

^a Academic Teaching Hospital Hall ^*  (Austria)

^b TUFTS MEDICAL CENTER   (United States)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF GUADALAJARA   (Mexico)

^e UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic liver disease; Cytokines; IL 1; IL 1 soluble receptors; Liver cirrhosis

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6;

ADULT; ARTICLE; CELL CULTURE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER CELL; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; HUMANS; INTERLEUKIN-1BETA; LIVER CIRRHOSIS; LIVER DISEASES; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-1 TYPE I; RECEPTORS, INTERLEUKIN-1 TYPE II;

EID: 54349097080     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520802179925     Document Type: Article

References (36)

1. Diehl AM. Cytokine regulation of liver injury and repair. Immunol Rev 2000;174:160-71.
2. Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992;103:264-74.
3. Tsutsui H, Matsui K, Okamura H, Nakanishi K. Pathophysiological roles of interleukin-18 in inflammatory liver diseases. Immunol Rev 2000;174:192-209.
4. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-76.
5. Bird GL, Sheron N, Goka AK, Alexander GJ, Williams RS. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990;112:917-20.
6. Felver ME, Mezey E, McGuire M, Mitchell MC, Herlong HF, Veech GA, et al. Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res 1990;14:255-9.
7. McClain CJ, Cohen DA, Dinarello CA, Cannon JG, Shedlofsky SI, Kaplan AM. Serum interleukin-1 (IL-1) activity in alcoholic hepatitis. Life Sci 1986;39:1479-85.
8. Hill DB, Marsano L, Cohen D, Allen J, Shedlofsky S, McClain CJ. Increased plasma interleukin-6 concentrations in alcoholic hepatitis. J Lab Clin Med 1992;119:547-52.
9. Sheron N, Bird G, Koskinas J, Portmann B, Ceska M, Lindley I, et al. Circulating and tissue levels of the neutrophil chemotaxin interleukin-8 are elevated in severe acute alcoholic hepatitis, and tissue levels correlate with neutrophil infiltration. Hepatology 1993;18:41-6.
10. Hassan G, Moreno S, Massimi M, Di Biagio P, Stefanini S. Interleukin-1-producing plasma cells in close contact with hepatocytes in patients with chronic active hepatitis. J Hepatol 1997;27:6-17.
11. Dinarello CA. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000;343:732-4.
12. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993;54:167-227.
13. Symons JA, Duff GW. A soluble form of the interleukin-1 receptor produced by a human B cell line. FEBS Lett 1990;272:133-6.
14. Symons JA, Eastgate JA, Duff GW. Purification and characterization of a novel soluble receptor for interleukin 1. J Exp Med 1991;174:1251-4.
15. Casini-Raggi V, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995;154:2434-40.
16. Youngman KR, Simon PL, West GA, Cominelli F, Rachmilewitz D, Klein JS, et al. Localization of intestinal interleukin 1 activity and protein and gene expression to lamina propria cells. Gastroenterology 1993;104:749-58.
17. Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990;343:336-40.
18. Dripps DJ, Brandhube BJ, Thompson RC, Eisenberg SP. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 1991;266:10331-6.
19. Ferretti M, Casini-Raggi V, Pizarro TT, Eisenberg SP, Nast CC, Cominelli F. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 1994;94:449-53.
20. Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest 1997;99:2930-40.
21. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993;328:106-13.
22. Giri JG, Newton RC, Horuk R. Identification of soluble interleukin-1 binding protein in cell-free supernatants. Evidence for soluble interleukin-1 receptor. J Biol Chem 1990;265:17416-9.
23. Arend WP, Malyak M, Smith MF, Jr, Whisenand TD, Slack JL, Sims JE, et al. Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol 1994;153:4766-74.
24. Symons JA, Young PR, Duff GW. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci USA 1995;92:1714-8.
25. Mullberg J, Rauch CT, Wolfson MF, Castner B, Fitzner JN, Otten-Evans C, et al. Further evidence for a common mechanism for shedding of cell surface proteins. FEBS Lett 1997;401:235-8.
26. Buger D, Chicheportiche R, Giri JG, Dayer JM. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest 1995;96:38-41.
27. Giri JG, Wells J, Dower SK, McCall CE, Guzman RN, Slack, et al. Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. J Immunol 1994;153:5802-9.
28. Preas HL, Reda D, Tropea M, Vandivier RW, Banks SM, Agosti JM, et al. Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. Blood 1996;88:2465-72.
29. Gabay C, Genin B, Mentha G, Iynedjian PB, Roux-Lombard P, Guerne PA. IL-1 receptor antagonist (IL-1Ra) does not inhibit the production of C-reactive protein or serum amyloid A protein by human primary hepatocytes. Differential regulation in normal and tumour cells. Clin Exp Immunol 1995;100:306-13.
30. Gabay C, Silacci P, Genin B, Mentha G, Le Coultre C, Guerne PA. Soluble interleukin-6 receptor strongly increases the production of acute-phase protein by hepatoma cells but exerts minimal changes on human primary hepatocytes. Eur J Immunol 1995;25:2378-83.
31. Seglen PO. Preparation of isolated rat liver cells. Methods Cell Biol 1976;13:29-83.
32. Jouvenne P, Vannier E, Dinarello CA, Miossec P. Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. Arthritis Rheum 1998;41:1083-9.
33. Ludwiczek O, Vannier E, Borggraefe I, Kaser A, Siegmund B, Dinarello CA, et al. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol 2004;138:323-9.
34. Poutsiaka DD, Clark BD, Vannier E, Dinarello CA. Production of interleukin-1 receptor antagonist and interleukin-1 beta by peripheral blood mononuclear cells is differentially regulated. Blood 1991;78:1275-81.
35. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
36. Smith RJ, Chin JE, Sam LM, Justen JM. Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum 1991;34:78-83.